Threshold Pharmaceuticals' TH-302 Continues to Demonstrate Promising Activity in Pancreatic Cancer Phase 1/2 Clinical Trial
January 24, 2011 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 24, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage...
Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results in Patients With Advanced Leukemias
December 22, 2010 08:35 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 22, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a preclinical collaboration with the MD Anderson Cancer Center and early Phase 1...
Follow-up Data From Threshold Pharmaceuticals' Phase 1/2 Clinical Trials of TH-302 Demonstrate Broad Activity in All Combinations Against Multiple Tumor Types
November 18, 2010 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 18, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Presents Promising Data From a Phase 1/2 Clinical Trial of TH-302 at International Sarcoma Meeting
November 12, 2010 08:25 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Announces Additional Medical and Investor Conference Presentations
November 09, 2010 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced additional meetings to its Fall conference presentation schedule. The Company will...
Threshold Pharmaceuticals Reports Third Quarter 2010 Financial and Operational Results
November 04, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the third quarter ended September 30, 2010.
The net loss...
Threshold Pharmaceuticals Awarded $488,958 in Grants Under Qualifying Therapeutic Discovery Project Program
November 03, 2010 09:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that the Company has been awarded a total of $488,958 in grants under the...
Threshold Pharmaceuticals Presents Follow-Up Data From a Phase 1/2 Clinical Trial of TH-302 in Solid Tumors
October 12, 2010 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced interim results from an ongoing Phase 1/2 clinical trial in various solid tumors...
Threshold to Present at Rodman & Renshaw Healthcare Conference
September 08, 2010 09:15 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the...
Threshold Pharmaceuticals Reports Second Quarter 2010 Financial and Operational Results
August 05, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2010.
The net loss for...